Dr at the Second Affiliated Hospital, Zhejiang University School of Medicine,Ā China
Hong-gang Lou is a distinguished pharmacologist and clinical pharmacology expert serving as the Deputy Director of the Clinical Pharmacology Center and Director of the Pharmaceutical Bioanalysis Laboratory at The Second Affiliated Hospital Zhejiang University School of Medicine. He has significantly contributed to the field of pharmacology through leadership roles in various professional societies and committees.
Publication Profile
Scopus
š Education
Hong-gang Lou completed his medical education at Zhejiang University, where he gained in-depth knowledge in pharmacology and medicine. He pursued advanced studies and training that equipped him with expertise in clinical pharmacology, pharmaceutical bioanalysis, and toxicology. His educational background forms the foundation for his influential career in medical research and clinical practice.
š¼ Experience
Since August 1992, Hong-gang Lou has held multiple key positions at The Second Affiliated Hospital Zhejiang University School of Medicine, including Deputy Director of Clinical Pharmacology and Director of the Pharmaceutical Bioanalysis Laboratory. He also serves as the Chairperson of the Pharmacological Toxicology Society of Zhejiang Toxicology Society and has played vital roles in various medical associations, enhancing clinical trials and ethical standards in the region.
š Awards and Honors
Throughout his career, Hong-gang Lou has received several awards recognizing his contributions to pharmacology and clinical research. His dedication to improving clinical practices and ensuring drug safety has earned him respect and accolades from peers in the medical community. He has also been acknowledged for his role in advancing ethical standards in clinical trials.
š Research Focus
Hong-gang Lou’s research focuses on clinical pharmacology, pharmaceutical bioanalysis, and toxicology. He investigates drug metabolism, pharmacokinetics, and the ethical implications of clinical trials, aiming to enhance drug safety and efficacy. His work significantly contributes to the understanding of pharmacological therapies, ultimately improving patient care and therapeutic outcomes.
Conclusion
Hong-gang Lou is a highly qualified candidate for the Best Researcher Award, characterized by his extensive experience, leadership in pharmacology, and commitment to ethical standards in clinical trials. His strong educational background and impactful research contributions position him as a leader in the field. By focusing on improving publication output, fostering interdisciplinary collaborations, and enhancing public outreach, Lou can further amplify his contributions to pharmacology and patient care. With these enhancements, he is well-equipped to make lasting impacts in the field and deserves recognition as an outstanding researcher.
Publication Top NotesĀ Ā
- Population Pharmacokinetic Analysis of Febuxostat with High Focus on Absorption Kinetics and Food Effect
- Chen, W., Jiang, B., Ruan, Z., Hu, Y., Lou, H. (2024)
- BMC Pharmacology and Toxicology, 25(1), 57.
- Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches
- Chen, W., Wang, L., Ruan, Z., Lou, H., Jiang, B. (2024)
- Journal of Pharmaceutical Sciences, 113(9), pp. 2915ā2921.
- Physiologically Based Absorption Modeling to Predict the Bioequivalence of Two Apixaban Formulations
- Luo, T., Wang, L., Ruan, Z., Zhao, P., Jiang, B. (2024)
- Clinical and Translational Science, 17(5), e13819.
- Bioequivalence Study of Epalrestat for Healthy Chinese Subjects
- Yang, D., Wang, X., Duan, Y., Lou, H., Chen, J. (2024)
- Clinical Pharmacology in Drug Development, 13(5), pp. 485ā490.
- Pharmacokinetics, Pharmacodynamics, and Safety of Frunexian in Healthy Chinese Volunteer Adults: A Randomized Dose-Escalation Phase I Study
- Zhang, J.-Y., Ruan, Z.-R., Jiang, B., Wang, L.-L., Lou, H.-G. (2024)
- Clinical and Translational Science, 17(4), e13787.
- Phase I Clinical Trial Evaluating the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of HSK21542 Injection in Healthy Volunteers
- Shao, R., Wang, H.-Y., Ruan, Z.-R., Yan, M., Lou, H. (2024)
- Basic and Clinical Pharmacology and Toxicology.
- In Silico Prediction of Bioequivalence of Atorvastatin Tablets Based on GastroPlusā¢ Software
- Wang, L., Chen, J., Chen, W., Yang, D., Jiang, B. (2023)
- BMC Pharmacology and Toxicology, 24(1), 69.
- Physiologically Based Absorption Modeling to Predict the Bioequivalence of Two Cilostazol Formulations
- Wang, L., Zhao, P., Luo, T., Ruan, Z., Jiang, B. (2023)
- Clinical and Translational Science, 16(11), pp. 2323ā2330.